Nightstar Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for NSR-REP1 in Choroideremia

World News: . []

First gene therapy RMAT designation for an inherited retinal disease STAR Phase 3 registrational trial ongoing and FDA interactions planned RMAT designation enables closer and more frequent multidisciplinary interaction with FDA with all of t he bene...

More news and information about Nightstar Therapeutics

Published By:

Thomson Reuters: 11:05 GMT Thursday 14th June 2018

Published: .

Search for other references to "nightstar" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us